학술논문
How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors.
Document Type
journal article
Author
Source
Progress in Cardiovascular Diseases; Jul2021, Vol. 67, p65-74, 10p
Subject
Language
ISSN
00330620
Abstract
Copyright of Progress in Cardiovascular Diseases is the property of W B Saunders and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)